Age: 50-79 and pathology circumferences level, ethnicity, years, report measured family history of W Incidence, colon cancer, colorectal HRT use, Q 2 vs Q 1 1.58 (1.26-1.97) cancer, HRT per week, never smoking, treatment allocation Incidence, 422/ colorectal 1.60 (1.18-2.16) 28 098 cancer, braf Ptrend:0.001 18 negative 101 vs 95 ≥ ≤ MDCS, cm Brändstedt, Age, sex, Incidence, Prospective 2014 Cancer registry alcohol, Gene-mutation colorectal 1.29 (0.91-1.83) Cohort, 314/ COL41022 educational data cancer, kras Ptrend:0.120 Age: 44-74 Sweden level, smoking negative M/W Incidence, colorectal 101 vs 95 1.98 (1.20-3.28) ≥ ≤ 179/ cancer, kras cm Ptrend:0.004 positive Incidence, NLCS, Simons, 2014 colorectal Case Cohort, 188/ COL41029 Cancer registry cancer, Igfbp 2 1.22 (0.84-1.75) Age: 55-69 Netherlands genes years methylated
Age: 50-79 years, W and pathology report circumferences measured level, ethnicity, family history of colon cancer, HRT use, per week, smoking, treatment allocation Incidence, colorectal cancer, HRT never Q 2 vs Q 1 1.58 (1.26-1.97) Brändstedt, 2014 COL41022 Sweden MDCS, Prospective Cohort, Age: 44-74 M/W 422/ 28 098 18 Cancer registry Incidence, colorectal cancer, braf negative ≥ 101 vs ≤ 95 cm 1.60 (1.18-2.16) Ptrend:0.001 Age, sex, alcohol, educational level, smoking Gene-mutation data 314/ Incidence, colorectal cancer, kras negative 1.29 (0.91-1.83) Ptrend:0.120 179/ Incidence, colorectal cancer, kras positive ≥ 101 vs ≤ 95 cm 1.98 (1.20-3.28) Ptrend:0.004 Simons, 2014 COL41029 Netherlands NLCS, Case Cohort, Age: 55-69 years 188/ Cancer registry Incidence, colorectal cancer, Igfbp 2 genes methylated 1.22 (0.84-1.75)
CUP_colorectal_SLR_2016_RO.docx